Overview
Ipamorelin and GHRP-6 are both synthetic growth hormone secretagogues that release GH through a GHRP-like (ghrelin-type) receptor. GHRP-6 is the earlier compound, and ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that was identified from a series of compounds lacking the central Ala-Trp dipeptide of GHRP-1 (Raun 1998). This page sets out what the published studies report for each and where they are silent. It is background for research use only.
Preclinical comparison: potency and efficacy
Raun 1998 compared ipamorelin with GHRP-6 in three systems.
| System | Ipamorelin | GHRP-6 |
|---|---|---|
| Rat pituitary cells, GH release in vitro | EC50 1.3 nmol/L, Emax 85% | EC50 2.2 nmol/L, Emax 100% |
| Anaesthetised rats | ED50 80 nmol/kg, Emax 1,545 ng GH/ml | ED50 115 nmol/kg, Emax 1,167 ng GH/ml |
| Conscious swine | ED50 2.3 nmol/kg, Emax 65 ng GH/ml | ED50 3.9 nmol/kg, Emax 74 ng GH/ml |
The paper describes ipamorelin as releasing GH with a potency and efficacy similar to GHRP-6, and as acting like GHRP-6 through a GHRP-like receptor.
Selectivity: ACTH, cortisol and other hormones
In swine, none of the secretagogues tested changed FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 raised plasma ACTH and cortisol. Ipamorelin did not release ACTH or cortisol at levels significantly different from those seen after GHRH stimulation, and this held even at doses more than 200-fold above the ED50 for GH release. The authors described ipamorelin as the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH (Raun 1998).
Human studies of GHRP-6 report ACTH and cortisol release. In 10 patients with Cushing disease, GHRP-6 (2 micrograms per kg intravenously) raised ACTH from 15.5 to a peak of 45.1 pmol/L and cortisol from 583 to 1,013 nmol/L (Oliveira 2003). In a study of ghrelin and GHRP-6 in 20 hyperthyroid patients and 9 controls, GHRP-6 produced cortisol and ACTH responses in both groups (Nascif 2009). These populations are patients, so the results may not apply to healthy subjects.
Pharmacokinetics
In healthy men (eight per dose level, five infusion rates from 4.21 to 140.45 nmol/kg over 15 minutes), ipamorelin showed dose-proportional kinetics with a terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. GH was released in a single episode that peaked at 0.67 hours and declined to negligible levels at all doses (Gobburu 1999).
In rats, ipamorelin had a systemic plasma clearance 5-fold lower than that of GHRP-6 after an intravenous bolus. After intranasal application, the bioavailability of ipamorelin was estimated at about 20%, and that of GHRP-6 was somewhat lower (Johansen 1998).
Appetite
Ghrelin and GH secretagogues including GHRP-6 are described as stimulating food intake and adiposity in rats (Granado 2010). In a separate small study, a GHRP-2 infusion increased the amount eaten at a buffet meal by 35.9% in seven lean men (Laferrere 2005). This guide does not cite data on appetite for ipamorelin.
A clinical study of ipamorelin
A multicentre, double-blind, placebo-controlled phase 2 trial of intravenous ipamorelin (0.03 mg/kg twice daily for up to 7 days) in 117 patients after bowel resection found no significant difference from placebo in the time to tolerate a first solid meal (median 25.3 versus 32.6 hours, p = 0.15). The drug was well tolerated, and the authors described the study as small proof-of-concept work (Beck 2014).
What the sources do not show
- No source checked for this guide compares ipamorelin and GHRP-6 head to head in humans.
- Receptor-binding constants (Ki values) and off-target receptor claims are not given, because the sources checked do not report them.
- The human data for ipamorelin cited here come from one pharmacokinetic study in healthy men and one small trial in surgical patients.
- This guide cites no data on combining either compound with a GHRH analogue. See the CJC-1295 DAC vs No DAC comparison for CJC-1295 as studied alone.
Research Formats Available Through Stackpure
Stackpure offers both secretagogues in multiple research-grade formulations to support diverse experimental configurations. For standard reconstitution-based in vitro and in vivo work, the Ipamorelin Peptide Vial and GHRP-6 Peptide Vial are supplied as lyophilised powder with ≥98% purity confirmed by HPLC and mass spectrometry. Certificate of Analysis documentation is available at Stackpure Lab Testing & COA.
For researchers requiring alternative administration routes in animal model work, the Ipamorelin Nasal Spray and GHRP-6 Nasal Spray provide pre-prepared aqueous formulations with defined peptide concentration per actuation. Nasal delivery formats are of particular utility in rodent intranasal bioavailability studies examining transmucosal peptide transport and CNS uptake kinetics.
Pre-mixed blend formats, including the ipamorelin/CJC-1295 and GHRP-6/CJC-1295 combinations, reduce preparation variables in long-duration experiments where consistent co-administration ratios are required. All products are manufactured under controlled conditions and are intended exclusively for qualified laboratory research.
Frequently Asked Questions
What is the difference between ipamorelin and GHRP-6?
In rats and swine, ipamorelin released GH with a potency and efficacy similar to GHRP-6. The clearest reported difference is selectivity: in swine, GHRP-6 raised ACTH and cortisol, while ipamorelin did not raise them at levels significantly different from GHRH stimulation (Raun 1998).
Does ipamorelin raise cortisol?
In the swine study, ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at more than 200-fold the ED50 for GH release (Raun 1998).
Does GHRP-6 raise cortisol?
Yes. GHRP-6 raised ACTH and cortisol in swine (Raun 1998) and in patients with Cushing disease (Oliveira 2003).
What is the half-life of ipamorelin in humans?
The terminal half-life was 2 hours in healthy men given 15-minute infusions (Gobburu 1999).
Has ipamorelin been tested in a clinical trial?
Yes, in a phase 2 trial in 117 patients after bowel resection. It was well tolerated, with no significant difference from placebo in the main efficacy measure (Beck 2014).
Key References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PubMed 10496658
- Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998. PubMed 9879640
- Oliveira HA, et al. GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing disease: comparison with DDAVP. J Endocrinol Invest. 2003. PubMed 12809173
- Nascif SO, et al. Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis. Pituitary. 2009. PubMed 19396632
- Granado M, et al. The positive effects of growth hormone-releasing peptide-6 on weight gain and fat mass accrual depend on the insulin status. Endocrinology. 2010. PubMed 20219977
- Laferrere B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005. PubMed 15699539
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PubMed 25331030
For research use only. Not for human consumption.